Hemab Therapeutics Holdings Inc. (COAG)

$34.00 +7.00 (25.93%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 4,094,694
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and s...

Industry: Biotechnology
Sector: Healthcare
Phone: (617) 553-3952
Address:
101 Main Street, Suite 1220, Cambridge, United States
topstockalerts
topstockalerts Jul. 17 at 9:09 PM
$COAG low key strong… might catch people off guard
0 · Reply
JFais
JFais Jul. 16 at 8:13 PM
$COAG yet another recent bio IPO outperforming
1 · Reply
STACKD0E
STACKD0E Jul. 14 at 9:35 PM
$COAG ✨
0 · Reply
STACKD0E
STACKD0E Jul. 14 at 12:03 PM
$SLB $LBRT $COAG $ZENA ✨️
0 · Reply
G101SPM
G101SPM Jul. 13 at 7:31 PM
#SHOWTIME International Society on Thrombosis and Haemostasis Congress (July 14) Scheduled to appear: $COAG Ophthalmology Innovation Source Retina Innovation Summit (July 14) Scheduled to appear: $OCUL, $OCGN, $OCS
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 12 at 10:22 PM
$COAG Another early Sunday morning headline on this Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress "HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing"
0 · Reply
justiceforb_85
justiceforb_85 Jul. 12 at 1:16 PM
$COAG strong data for other clinical assets. https://ir.hemab.com/news-releases/news-release-details/hemab-therapeutics-presents-new-clinical-data-hmb-002-von
0 · Reply
umar994
umar994 Jul. 9 at 4:21 PM
$COAG anyone following this stock on the run up to their oral presentations at ISTH next week?
1 · Reply
LongMoneyMovements
LongMoneyMovements Jun. 29 at 6:23 PM
$SLS Destination $15 Leader of the pack $OGN $ODTX $COAG $OCGN $SLS
0 · Reply
LongMoneyMovements
LongMoneyMovements Jun. 29 at 6:19 PM
$OGN $ODTX $COAG $OCGN $SLS
0 · Reply
Latest News on COAG
Hemab Therapeutics presents sutacimig data at ISTH Congress

2026-07-14T11:50:16.000Z - 15 days ago

Hemab Therapeutics presents sutacimig data at ISTH Congress

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Jul 14, 2026, 7:45 AM EDT - 15 days ago

Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress

Hemab Therapeutics price target raised to $47 from $39 at Jefferies

2026-07-13T12:55:09.000Z - 16 days ago

Hemab Therapeutics price target raised to $47 from $39 at Jefferies

INCY

Hemab Therapeutics price target raised to $55 from $42 at Wedbush

2026-07-13T12:10:23.000Z - 16 days ago

Hemab Therapeutics price target raised to $55 from $42 at Wedbush

Hemab Therapeutics price target raised to $52 from $40 at H.C. Wainwright

2026-07-13T10:11:59.000Z - 16 days ago

Hemab Therapeutics price target raised to $52 from $40 at H.C. Wainwright

Hemab Therapeutics presents new clinical data from HMB-002 in VWD

2026-07-12T13:45:09.000Z - 17 days ago

Hemab Therapeutics presents new clinical data from HMB-002 in VWD

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Jul 12, 2026, 6:28 AM EDT - 17 days ago

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

Jun 26, 2026, 9:00 AM EDT - 4 weeks ago

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

Hemab Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-17T10:06:44.000Z - 6 weeks ago

Hemab Therapeutics initiated with a Buy at H.C. Wainwright

Hemab Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 9:20 AM EDT - 7 weeks ago

Hemab Therapeutics Holdings Transcript: Jefferies Global Healthcare Conference 2026

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

May 27, 2026, 8:00 AM EDT - 2 months ago

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Hemab Therapeutics initiated with an Outperform at Evercore ISI

2026-05-26T14:53:50.000Z - 2 months ago

Hemab Therapeutics initiated with an Outperform at Evercore ISI

Wedbush bullish on Hemab Therapeutics, initiates with an Outperform

2026-05-26T14:22:55.000Z - 2 months ago

Wedbush bullish on Hemab Therapeutics, initiates with an Outperform

Hemab Therapeutics initiated with an Outperform at Wedbush

2026-05-26T12:08:58.000Z - 2 months ago

Hemab Therapeutics initiated with an Outperform at Wedbush

Hemab Therapeutics initiated with a Buy at Jefferies

2026-05-26T09:15:41.000Z - 2 months ago

Hemab Therapeutics initiated with a Buy at Jefferies

Hemab Therapeutics initiated with a Buy at Goldman Sachs

2026-05-26T08:25:04.000Z - 2 months ago

Hemab Therapeutics initiated with a Buy at Goldman Sachs

Hemab Therapeutics Holdings Earnings release: Q1 2026

May 21, 2026, 7:00 AM EDT - 2 months ago

Hemab Therapeutics Holdings Earnings release: Q1 2026

Hemab Therapeutics Holdings Quarterly report: Q1 2026

May 21, 2026, 7:00 AM EDT - 2 months ago

Hemab Therapeutics Holdings Quarterly report: Q1 2026

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 4, 2026, 4:01 PM EDT - 3 months ago

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Hemab Therapeutics opens at $27, IPO priced at $18 per share

2026-05-01T16:35:27.000Z - 3 months ago

Hemab Therapeutics opens at $27, IPO priced at $18 per share

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Apr 30, 2026, 6:55 PM EDT - 3 months ago

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Hemab Therapeutics Holdings IPO Registration Document (S-1)

Apr 10, 2026, 4:41 PM EDT - 3 months ago

Hemab Therapeutics Holdings IPO Registration Document (S-1)

topstockalerts
topstockalerts Jul. 17 at 9:09 PM
$COAG low key strong… might catch people off guard
0 · Reply
JFais
JFais Jul. 16 at 8:13 PM
$COAG yet another recent bio IPO outperforming
1 · Reply
STACKD0E
STACKD0E Jul. 14 at 9:35 PM
$COAG ✨
0 · Reply
STACKD0E
STACKD0E Jul. 14 at 12:03 PM
$SLB $LBRT $COAG $ZENA ✨️
0 · Reply
G101SPM
G101SPM Jul. 13 at 7:31 PM
#SHOWTIME International Society on Thrombosis and Haemostasis Congress (July 14) Scheduled to appear: $COAG Ophthalmology Innovation Source Retina Innovation Summit (July 14) Scheduled to appear: $OCUL, $OCGN, $OCS
0 · Reply
AlertsAndNews
AlertsAndNews Jul. 12 at 10:22 PM
$COAG Another early Sunday morning headline on this Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress "HMB-002 clinical data demonstrate proof of mechanism, with dose-dependent, greater than or equal to 2.4-fold peak increases in Von Willebrand Factor (VWF) and Factor VIII (FVIII), normalization of peak thrombin generation and activated partial thromboplastin time (APTT), and durability supporting potential monthly subcutaneous dosing"
0 · Reply
justiceforb_85
justiceforb_85 Jul. 12 at 1:16 PM
$COAG strong data for other clinical assets. https://ir.hemab.com/news-releases/news-release-details/hemab-therapeutics-presents-new-clinical-data-hmb-002-von
0 · Reply
umar994
umar994 Jul. 9 at 4:21 PM
$COAG anyone following this stock on the run up to their oral presentations at ISTH next week?
1 · Reply
LongMoneyMovements
LongMoneyMovements Jun. 29 at 6:23 PM
$SLS Destination $15 Leader of the pack $OGN $ODTX $COAG $OCGN $SLS
0 · Reply
LongMoneyMovements
LongMoneyMovements Jun. 29 at 6:19 PM
$OGN $ODTX $COAG $OCGN $SLS
0 · Reply
LongMoneyMovements
LongMoneyMovements Jun. 29 at 6:05 PM
$ODTX $COAG $OCGN $ODTX
0 · Reply
topstockalerts
topstockalerts Jun. 27 at 12:28 AM
$COAG the move looks more deliberate than random.
0 · Reply
justiceforb_85
justiceforb_85 Jun. 26 at 4:37 PM
$COAG great update from the company. Look forward to HMB-002 data in VWD.
0 · Reply
justiceforb_85
justiceforb_85 Jun. 19 at 2:35 AM
$COAG awesome movement today.
0 · Reply
MarketBeat
MarketBeat Jun. 9 at 3:05 AM
https://marketbeat.com/a/8701474/ $COAG Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 5 at 5:10 PM
$COAG Really good write-up that perfectly summarizes COAG's present situation. So if you want to bring your COAG knowledge up to date or just discover COAG, this is required reading. https://everyticker.com/quote/COAG/analysis/hemab-s-1-3b-bet-can-a-differentiated-antibody-platform-overcome-thrombosis-risks-to-dominate-rare-bleeding-disorders-nasdaq-coag
0 · Reply
justiceforb_85
justiceforb_85 May. 26 at 9:47 PM
$COAG strong day. Solid funding and good data for sutacimig in GT where they would have a MOAT.
0 · Reply
notreload_ai
notreload_ai May. 26 at 10:02 AM
Jefferies initiates Buy rating on $COAG with $39 target (~50% upside). Sees Hemlibra-like potential in rare bleeding disorders. https://notreload.xyz/xy/jefferies-sees-hemlibra-like-potential-in-hemab-therapeutics-starts-coverage-with-buy-rating/
0 · Reply
justiceforb_85
justiceforb_85 May. 4 at 4:35 PM
$COAG interesting pipeline.
0 · Reply
topstockalerts
topstockalerts May. 3 at 11:08 PM
Top Gainers $AIOS $CUE $COAG $SOBR $ESPR
0 · Reply
Investor203
Investor203 May. 3 at 7:34 PM
$COAG $CUE i think $VNDA will be $25-$30 soon. Sleeping giant and yes I have over 23,000 shares sofar. Planning to accumulate another 7,000 by EOY.
0 · Reply